Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies

Adam S. Kittai; Scott Best; Bria Thurlow; Vi Lam; Taylor Hashiguchi; Shaun Goodyear; Daniel O. Persky; Craig Okada; Byung Park; Stephen E. Spurgeon; Alexey V. Danilov

doi:10.3324/haematol.2020.270298

Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies

Adam S. Kittai, Scott Best, Bria Thurlow, Vi Lam, Taylor Hashiguchi, Shaun Goodyear, Daniel O. Persky, Craig Okada, Byung Park, Stephen E. Spurgeon, Alexey V. Danilov

Research output: Contribution to journal › Letter › peer-review

6 Scopus citations

Original language	English (US)
Pages (from-to)	2022-2025
Number of pages	4
Journal	Haematologica
Volume	106
Issue number	7
DOIs	https://doi.org/10.3324/haematol.2020.270298
State	Published - Jul 2021

ASJC Scopus subject areas

Hematology

Access to Document

10.3324/haematol.2020.270298

Cite this

@article{2bf87162336043abbde6470f8b9c021d,

title = "Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies",

author = "Kittai, {Adam S.} and Scott Best and Bria Thurlow and Vi Lam and Taylor Hashiguchi and Shaun Goodyear and Persky, {Daniel O.} and Craig Okada and Byung Park and Spurgeon, {Stephen E.} and Danilov, {Alexey V.}",

note = "Funding Information: Funding: this Investigator-sponsored study was funded by Gilead Sciences Inc and Roche/Genentech; AVD was supported in part by the Leukemia & Lymphoma Society Scholar in Clinical Research Award #2319-19. Funding Information: we extend our thanks to the patients and their families. We would also like to thank Sarah Dreumont, Basak Gokcora, Renee MacKinnon, Kirsten Orand, Bethany Wollam, Nan Subbiah, Stephen Monette, Lacy Moore, Debbie Ryan and the rest of the lymphoma team at Oregon Health and Science University for their contribution to this study.",

year = "2021",

month = jul,

doi = "10.3324/haematol.2020.270298",

language = "English (US)",

volume = "106",

pages = "2022--2025",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "7",

}

TY - JOUR

T1 - Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies

AU - Kittai, Adam S.

AU - Best, Scott

AU - Thurlow, Bria

AU - Lam, Vi

AU - Hashiguchi, Taylor

AU - Goodyear, Shaun

AU - Persky, Daniel O.

AU - Okada, Craig

AU - Park, Byung

AU - Spurgeon, Stephen E.

AU - Danilov, Alexey V.

N1 - Funding Information: Funding: this Investigator-sponsored study was funded by Gilead Sciences Inc and Roche/Genentech; AVD was supported in part by the Leukemia & Lymphoma Society Scholar in Clinical Research Award #2319-19. Funding Information: we extend our thanks to the patients and their families. We would also like to thank Sarah Dreumont, Basak Gokcora, Renee MacKinnon, Kirsten Orand, Bethany Wollam, Nan Subbiah, Stephen Monette, Lacy Moore, Debbie Ryan and the rest of the lymphoma team at Oregon Health and Science University for their contribution to this study.

PY - 2021/7

Y1 - 2021/7

UR - http://www.scopus.com/inward/record.url?scp=85110447757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85110447757&partnerID=8YFLogxK

U2 - 10.3324/haematol.2020.270298

DO - 10.3324/haematol.2020.270298

M3 - Letter

C2 - 33504141

AN - SCOPUS:85110447757

SN - 0390-6078

VL - 106

SP - 2022

EP - 2025

JO - Haematologica

JF - Haematologica

IS - 7

ER -

Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this